Vitamin D and breast cancer: Emerging concepts

Cancer Letters

Volumn 334, Issue 1, 2013, Pages 95-100

  Mehta, Rajendra G ^a   Peng, Xinjian ^a   Alimirah, Fatouma ^a   Murillo, Genoveva ^a   Mehta, Rajeshwari ^a  

^a IIT RESEARCH INSTITUTE   (United States)

Author keywords

Breast cancer; VDR; Vitamin D

Indexed keywords

CALCITRIOL; MICRORNA; VITAMIN D; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; COLECALCIFEROL 24 HYDROXYLASE; CYP24A1 PROTEIN, HUMAN;

BREAST CANCER; CANCER RISK; CELL PROLIFERATION; CYP24A GENE; DRUG MECHANISM; GENE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; MITOSIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; RNA SPLICING; SHORT SURVEY; VDR GENE; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY;

BREAST NEOPLASMS; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MICRORNAS; POLYMORPHISM, GENETIC; RECEPTORS, CALCITRIOL; VITAMIN D; VITAMIN D3 24-HYDROXYLASE;

EID: 84891930231     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.10.034     Document Type: Review

References (56)

1. Mellanby E. An experimental investigation on rickets. The Lancet 1919, 1:407-412.
2. Mellanby E. An experimental investigation on rickets. Nutr. Rev. 2009, 34:338-340.
3. Napoli J.L., Fivizzani M.A., Schnoes H.K., DeLuca H.F. Synthesis of vitamin D5: its biological activity relative to vitamins D3 and D2. Arch. Biochem. Biophys. 1979, 197:119-125.
4. Cheung F.S., Lovicu F.J., Reichardt J.K. Current progress in using vitamin D and its analogs for cancer prevention and treatment. Expert Rev. Anticancer Ther. 2012, 12:811-837.
5. Battault S., Whiting S.J., Peltier S.L., Sadrin S., Gerber G., Maixent J.M. Vitamin D metabolism, functions and needs: from science to health claims. Eur. J. Nutr. 2012, (August 12).
6. Thorne J., Campbell M.J. The vitamin D receptor in cancer. Proc. Nutr. Soc. 2008, 67:15-27.
7. Nair-Shalliker V., Clements M., Fenech M., Armstrong B.K. Personal sun exposure and serum 25-hydroxy vitamin D concentrations. Photochem. Photobiol. 2012, July. 10.1111/j.1751-1097.2012.01201.x.
8. Gilbert R., Martin R.M., Fraser W.D., Lewis S., Donovan J., Hamdy F., Neal D.E., Lane J.A., Metcalfe C. Predictors of 25-hydroxyvitamin D and its association with risk factors for prostate cancer: evidence from the prostate testing for cancer and treatment study. Cancer Causes Contr. 2012, 23:575-588.
9. Krishnan A.V., Feldman D. Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu. Rev. Pharmacol. Toxicol. 2011, 51:311-336.
10. Freedman D.M., Chang S.C., Falk R.T., Purdue M.P., Huang W.Y., McCarty C.A., Hollis B.W., Graubard B.I., Berg C.D., Ziegler R.G. Serum levels of vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol. Biomar. Prev. 2008, 17:889-894.
11. Welsh J. Vitamin D metabolism in mammary gland and breast cancer. Mol. Cell Endocrinol. 2011, 347:55-60.
12. Jones G. Vitamin D analogs. Endocrinol. Metab. Clin. North Am. 2010, 39:447-472.
13. Chiellini G., DeLuca H.F. The importance of stereochemistry on the actions of vitamin D. Curr. Top Med. Chem. 2011, 11:840-859.
14. Agoston E.S., Hatcher M.A., Kensler T.W., Posner G.H. Vitamin D analogs as anti-carcinogenic agents. Anticancer Agents Med. Chem. 2006, 6:53-71.
15. Hussain E.A., Mehta R.R., Ray R., Das Gupta T.K., Mehta R.G. Efficacy and mechanism of action of 1alpha-hydroxy-24-ethyl-cholecalciferol (1alpha[OH]D5) in breast cancer prevention and therapy. Recent Results Cancer Res. 2003, 164:393-411.
16. Spina C.S., Tangpricha V., Uskokovic M., Adorinic L., Maehr H., Holick M.F. Vitamin D and cancer. Anticancer Res. 2006, 26:2515-2524.
17. Pinette K.V., Yee Y.K., Amegadzie B.Y., Nagpal S. Vitamin D receptor as a drug discovery target. Mini Rev. Med. Chem. 2003, 3:193-204.
18. Mehta R.G. Experimental basis for the prevention of breast cancer. Eur. J. Cancer 2000, 36:1275-1282.
19. Choi M., Makishima M. Therapeutic applications for novel non-hypercalcemic vitamin D receptor ligands. Expert Opin. Ther. Pat. 2009, 19:593-606.
20. Mehta R.G. Stage-specific inhibition of mammary carcinogenesis by 1alpha-hydroxyvitamin D5. Eur. J. Cancer 2004, 40:2331-2337.
21. Mehta R.G., Hussain E.A., Mehta R.R., Das Gupta T.K. Chemoprevention of mammary carcinogenesis by 1alpha-hydroxyvitamin D5, a synthetic analog of Vitamin D. Mutat. Res. 2003, 523-524:253-264.
22. Lee H.J., Paul S., Atalla N., Thomas P.E., Lin X., Yang I., Buckley B., Lu G., Zheng X., Lou Y.R., Conney A.H., Maehr H., Adorini L., Uskokovic M., Suh N. Gemini vitamin D analogues inhibit estrogen receptor-positive and estrogen receptor-negative mammary tumorigenesis without hypercalcemic toxicity. Cancer Prev. Res. 2008, 1:476-484.
23. Koshizuka K., Koike M., Asou H., Cho S.K., Stephen T., Rude R.K., Binderup L., Uskokovic M., Koeffler H.P. Combined effect of vitamin D3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo. Breast Cancer Res. Treat. 1999, 53:113-120.
24. Zinser G.M., Suckow M., Welsh J. Vitamin D receptor (VDR) ablation alters carcinogen-induced tumorigenesis in mammary gland, epidermis and lymphoid tissues. J. Steroid Biochem. Mol. Biol. 2005, 97:153-164.
25. Alimirah F., Vaishnav A., McCormick M., Echchgadda I., Chatterjee B., Mehta R.G., Peng X. Functionality of unliganded VDR in breast cancer cells: repressive action on CYP24 basal transcription. Mol. Cell Biochem. 2010, 342:143-150.
26. Haussler M.R., Whitfield G.K., Kaneko I., Haussler C.A., Hsieh D., Hsieh J.C., Jurutka P.W. Molecular mechanisms of vitamin D action. Calcif. Tissue Int. 2012, (July 11).
27. Lösel R., Wehling M. Nongenomic actions of steroid hormones. Nat. Rev. Mol. Cell Biol. 2003, 4:46-55.
28. 3: genomic and non-genomic Mechanisms. Best Pract. Res. Clin. Endocrinol. Metab. 2011, 25:543-559.
29. Fleet J.C., DeSmet M., Johnson R., Li Y. Vitamin D and cancer: a review of molecular mechanisms. Biochem. J. 2012, 441:61-76.
30. Krishanan A.V., Trump D.L., Johnson C.S., Feldman D. The role of vitamin D in cancer prevention and therapy. Endocr. Metabol. Clin N. Am. 2010, 39:401-418.
31. Gulliford T., English J., Colston K.W., Menday P., Moller S., Combes R.C. A Phase I study of vitamin D analog EB1089 in patients with advanced breast and colorectal cancer. Br. J. Cancer 1998, 78:6-13.
32. Vijayakumar S., Boerner P.S., Mehta R.R., Packianathan S., Mehta R.G., Das T.K. Gupta clinical trials using chemopreventive vitamin D analogs in breast cancer. Cancer J. 2006, 12:445-450.
33. Peng X., Vaishnav A., Murillo G., Alimirah F., Torres K.E., Mehta R.G. Protection against cellular stress by 25-hydroxyvitamin D3 in breast epithelial cells. J. Cell Biochem. 2010, 110:1324-1333.
34. Zhang X., Li P., Bao J., Nicosia S.V., Wang H., Enkemann S.A., Bai W. Suppression of death receptor-mediated apoptosis by 1,25-dihydroxyvitamin D3 revealed by microarray analysis. J. Biol. Chem. 2005, 280:33458-33468.
35. Maruyama R., Aoki F., Toyota M., Sasaki Y., Akashi H., Mita H., Suzuki H., Akino K., Ohe-Toyota M., Maruyama Y., Tatsumi H., Imai K., Shinomura Y., Tokino T. Comparative genome analysis identifies the vitamin D receptor gene as a direct target of p53-mediated transcriptional activation. Cancer Res. 2006, 66:4574-4583.
36. Vousden K.H. Activation of the p53 tumor suppressor protein. Biochem. Biophys. Acta 2002, 1602:47-59.
37. Yan C., Lu D., Hai T., Boyd D.D. Activation transcription factor 3, stress sensor, activates p53 by blocking its ubiquitination. EMBO J. 2005, 24:2425-2435.
38. Qi X., Pramanik R., Wang J., Schultz R.M., Maitra R.K., Han J., DeLuca H.F., Chen G. The p38 and JNK pathways cooperate to trans-activate vitamin D receptor via c-Jun/AP-1 and sensitize human breast cancer cells to vitamin D(3)-induced growth inhibition. J. Biol. Chem. 2002, 277:25884-25892.
39. Köstner K., Denzer N., Müller C.S., Klein R., Tilgen W., Reichrath J. The relevance of vitamin D receptor (VDR) gene polymorphisms for cancer: a review of the literature. Anticancer Res. 2009, 29:3511-3536.
40. Whitfield G.K., Remus L.S., Jurutka P.W., Zitzer H., Oza A.K., Dang H.T., Haussler C.A., Galligan M.A., Thatcher M.L., Encinas Dominguez C., Haussler M.R. Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Mol. Cell Endocrinol. 2001, 177:145-159.
41. Guy M., Lowe L.C., Bretherton-Watt D., Mansi J.L., Peckitt C., Bliss J., Wilson R.G., Thomas V., Colston K.W. Vitamin D receptor gene polymorphisms and breast cancer risk. Clin. Cancer Res. 2004, 10:5472-5481.
42. Chen W.Y., Berone-Johnson E.R., Hunter D.J., Willett W.C., Hankinson S.E. Association between polymorphism in the vitamin D receptor and breast cancer risk. Cancer Epidemiol. Biomar. Prev. 2005, 14:2335-2339.
43. Raimondi S., Johansson H., Maisonneuve P., Gandini S. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis 2009, 30:1170-1180.
44. Tang C., Chen N., Wu M., Yuan H., Du Y. FokI polymorphism of vitamin D receptor gene contributes to breast cancer susceptibility: a meta-analysis. Breast Cancer Res. Treat. 2009, 117:391-399.
45. Alimirah F., Peng X., Murillo G., Mehta R.G. Functional significance of vitamin D receptor FokI polymorphism in human breast cancer cells. PLoS One 2011, 6:e16024.
46. King A.N., Beer D.G., Christensen P.J., Simpson R.U., Ramnath N. The vitamin D/CYP24A1 story in cancer. Anticancer Agents Med. Chem. 2010, 10:213-224.
47. Hoskins A.A., Moore M.J. The spliceosome: a flexible, reversible macromolecular machine. Trends Biochem. Sci. 2012, 37:179-188.
48. Zhang C., Dowd D.R., Staal A., Gu C., Lian J.B., Wijnen A.J., Stein G.S., McDonald P.N. Nuclear coactivator-62 kDa/Ski-interacting protein is a nuclear matrix-associated coactivator that may couple vitamin D receptor-mediated transcription and RNA splicing. J. Biol. Chem. 2003, 278:35325-35336.
49. Peng X., Tiwari N., Roy S., Yuan L., Murillo G., Mehta R.R., Benya R.V., Mehta R.G. Regulation of CYP24 splicing by 1,25-dihydroxyvitamin D3 in human colon cancer cells. J. Endocrinol. 2012, 212:207-215.
50. Kong Y.W., Ferland-McCollough D., Jackson T.J., Bushell M. MicroRNAs in cancer management. Lancet Oncol. 2012, 13:e249-e258.
51. Neelakandan K., Babu P., Nair S. Emerging roles for modulation of microRNA signatures in cancer chemoprevention. Curr. Cancer Drug. Targets 2012, 12:716-740.
52. Alvarez-Díaz S., Valle N., Ferrer-Mayorga G., Lombardía L., Herrera M., Domínguez O., Segura M.F., Bonilla F., Hernando E., Muñoz A. MicroRNA-22 is induced by vitamin D and contributes to its antiproliferative, antimigratory and gene regulatory effects in colon cancer cells. Human Mol. Genet. 2012, 21:2157-2165.
53. Komagata S., Nakajima M., Takagi S., Mohri T., Taniya T., Yokoi T. Human CYP24 catalyzing the inactivation of calcitriol is posttranscriptionally regulated by miR-125b. Mol. Pharmacol. 2009, 76:702-709.
54. Mohri T., Nakajima M., Takagio S., Komagata S., Yokoi T. MicroRNA regulates human vitamin D receptor. Int. J. Cancer 2009, 125:1328-1333.
55. R. Kasiappan, Z. Shen, A.K. Tse, U. Jinwal, J. Tang, P. Lungchukiet, Y. Sun, P. Kruk, S.V. Nicosia, X. Zhang, W. Bai, 1,25-dihydroxyvitamin D3 suppresses telomerase expression and human cancer growth through microRNA-498.
56. Jorde R., Svartberg J., Joakimsen R.M., Coucheron D.H. Plasma profile of microRNA after supplementation with high doses of vitamin D3 for 12months. BMC Res. Notes 2012, 17:245.